青少年和青年慢性难治性免疫性血小板减少症
本研究从三个大型登记处提取2004至2021年间12-25岁慢性原发性ITP患者数据,评估至48个月随访。427例中,12个月和48个月时分别有7%和14%被归类为难治性。难治组男性比例更高(43% vs 35%),血小板计数中位数更低、出血更多、治疗需求更高。
要点
- 12-25岁慢性ITP患者中,12个月时7%、48个月时14%为难治性。
- 难治组男性比例43% vs 非难治组35%。
- 难治组在初诊和随访中各时间点疾病负担均更高。
核心结论
- 青少年和青年中难治性ITP不常见,但难治性患者在所有时间点包括初诊时均显示高疾病负担。
研究设计与样本
- 从三个大型登记处提取2004至2021年间12-25岁、12个月时诊断为慢性原发性ITP的患者数据,评估至48个月随访。
- 共纳入427例慢性ITP患者,64%为女性。
- 难治性ITP定义为接受≥3种不同线治疗。
主要发现
- 12个月随访时7%被归类为难治性,48个月随访时14%被归类为难治性。
- 难治组男性比例43% vs 非难治组35%。
- 难治性患者较非难治性患者在初诊和随访时血小板计数中位数更低、出血更多、治疗需求更高。
关键数值与推荐
- 难治性ITP定义为接受≥3种不同线治疗。
- 12个月时难治性比例为7%,48个月时为14%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Defining immune thrombocytopenia (ITP) in two age groups-children and adults-overlooks the specific clinical features and needs of adolescents and young adults (AYAS). We previously reported a high risk of chronic disease at 12 months (50%); however, data on the course of chronic ITP, the risk of refractoriness and treatment strategies in AYAS are limited. Data from patients aged 12-25 years with chronic primary ITP at 12 months were extracted from three large registries between 2004 and 2021. Clinical and laboratory data were evaluated until 48 months of follow-up (FU). Refractory ITP was defined as the administration of ≥3 different lines of therapy. A total of 427 AYAS (64% female) with chronic ITP were included. Overall, 7% and 14% were classified as 'refractory' at 12 and 48 months of FU respectively. The proportion of males was greater in the refractory group than in the non-refractory group (43% vs. 35%). AYAS with refractory disease displayed lower median platelet counts, more bleeding and a higher need for treatment at initial diagnosis and FU than non-refractory patients. This study reveals that refractory ITP is uncommon in AYAS; however, AYAS with refractory ITP display a high disease burden at all time points, including at initial diagnosis.
引用
- Schifferli A, Le Gavrian G, Aladjidi N, et al. Chronic refractory immune thrombocytopenia in adolescents and young adults. Br J Haematol. 2023. PMID: 37735549. doi:10.1111/bjh.19081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。